Should anticoagulation be used for amaurosis fugax, or is antiplatelet therapy preferred unless a cardio‑embolic source such as atrial fibrillation, a mechanical heart valve, or a left‑ventricular thrombus is identified?

Antiplatelet Therapy is Preferred for Amaurosis Fugax Unless a Cardioembolic Source is Identified

For amaurosis fugax, antiplatelet therapy (aspirin 75-325 mg daily or clopidogrel 75 mg daily) is the recommended treatment, with anticoagulation reserved exclusively for patients with identified cardioembolic sources such as atrial fibrillation, mechanical heart valves, or left ventricular thrombus. 1, 2

Treatment Algorithm

Step 1: Rule Out Cardioembolic Sources

Immediately evaluate for:

• Atrial fibrillation (ECG, prolonged cardiac monitoring if indicated)
• Mechanical heart valve
• Left ventricular thrombus (echocardiography)
• Venous thromboembolic disease

Step 2: Treatment Based on Findings

If cardioembolic source identified:

• Initiate anticoagulation with warfarin (INR 2.0-3.0) 1, 2
• For atrial fibrillation specifically, direct oral anticoagulants are preferred over warfarin in nonvalvular cases 3
• Patients already on low-dose aspirin for atherosclerosis should continue it alongside anticoagulation 1

If NO cardioembolic source (the majority of cases):

• Start antiplatelet monotherapy: aspirin 75-325 mg daily OR clopidogrel 75 mg daily 1, 2
• Alternative: aspirin plus extended-release dipyridamole (25/200 mg twice daily) 1
• Do NOT use anticoagulation - antiplatelet therapy is explicitly recommended in preference to anticoagulants for atherosclerotic disease 1, 2

Clinical Reasoning

The evidence strongly supports antiplatelet therapy as first-line for amaurosis fugax because:

1. Amaurosis fugax represents transient retinal ischemia, typically from extracranial carotid or vertebral atherosclerosis 1, 2

2. Guidelines explicitly state that antiplatelet therapy is recommended in preference to anticoagulation for treating atherosclerotic vascular disease (Level of Evidence: A) 1, 2

3. Anticoagulation carries higher bleeding risk without proven benefit unless a specific cardioembolic source exists 1, 2

4. Recent observational data shows that in contemporary cohorts, 78% of amaurosis fugax patients receive antiplatelet therapy with only 2.2% receiving anticoagulation, with an 8.8% recurrence rate over 3.5 years 4

Critical Caveats

Carotid stenosis evaluation is mandatory: Patients with ipsilateral internal carotid artery stenosis ≥70-99% should be urgently evaluated for carotid endarterectomy if surgical risk is <6% 3. Amaurosis fugax with significant carotid disease is not innocuous - untreated patients face 21.9% cumulative morbidity versus 6.4% with surgical intervention 5.

Young patients (<45 years) without identifiable cause: Consider thrombophilia workup, particularly if multiple episodes occur. Small case series suggest antiphospholipid antibodies may be causative, and these patients may benefit from anticoagulation 6, 7. However, this represents a minority and requires hematology consultation.

Monitoring requirements differ:

• Warfarin requires weekly INR monitoring initially, then monthly when stable 1, 2
• Antiplatelet therapy requires no routine monitoring
• Triple therapy (warfarin + aspirin + clopidogrel) significantly increases bleeding risk and should be avoided unless absolutely necessary 1, 2

What NOT to Do

• Do not empirically anticoagulate without identifying a cardioembolic source - this increases bleeding risk without proven benefit 1, 2
• Do not use combination aspirin + clopidogrel routinely - this is only indicated post-ACS or post-PCI with stenting 1, 2
• Do not delay carotid imaging - significant stenosis requires urgent surgical evaluation 3